Clinical Trials
3 trialsNCT07397819 2026-02-09
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07007988 2025-06-06
SIM0388-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06433869 2024-05-30
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
Sun Yat-sen University
Phase 2 Recruiting